Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Ilika secures purchase order for Stereax electrodes
(Sharecast News) - Ilika said on Wednesday that it has secured its first revenue-generating purchase order for Stereax electrodes from Cirtec Medical, marking the commercial transition of the companies' strategic partnership after two years of development work. The AIM-traded solid-state battery specialist said the order covered supply of the conductive electrodes used in its Stereax M300 batteries and followed the successful delivery of prototype units in December.
It said the electrodes would support Cirtec's ramp-up of Stereax M300 production in the US, targeting applications across active implantable medical devices, including implanted sensors, neurostimulators, orthopaedic and orthodontic devices and ophthalmology applications.
Ilika said the order represented its entry into the commercial phase for its medical battery technology.
Under an agreement announced in August 2023, Ilika retained specific battery manufacturing processes at its UK facility as a service to Cirtec, while primary manufacturing of the Stereax M300 takes place at Cirtec's Massachusetts site.
With early batteries delivered late last year, the relationship had now progressed to Cirtec purchasing production quantities of electrodes from Ilika.
The Stereax M300 batteries were currently being evaluated by 21 customers.
"This marks an important transition from the earlier stages of technology transfer to commercial production coordinated from our facility here in the US," said Shawn Martin, vice president at Cirtec Medical.
Ilika chief executive Graeme Purdy said the receipt of the first commercial electrode order validated the "strong market momentum" building behind the Stereax technology.
"This revenue-generating phase of our partnership with Cirtec positions us to support their manufacturing scale-up while accelerating product integration across numerous high-value medical device applications," he said.
At 1458 GMT, shares in Ilika were up 2.33% at 37.35p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
